Top-Rated StocksTop-RatedNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free GH Stock Alerts $17.31 +0.15 (+0.87%) (As of 03:28 PM ET) Add Compare Share Share Today's Range$16.77▼$17.5250-Day Range$16.07▼$22.8352-Week Range$15.81▼$41.06Volume423,129 shsAverage Volume1.88 million shsMarket Capitalization$2.11 billionP/E RatioN/ADividend YieldN/APrice Target$39.27 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside125.2% Upside$39.27 Price TargetShort InterestBearish7.85% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment0.32Based on 15 Articles This WeekInsider TradingAcquiring Shares$38,972 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.49) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector95th out of 908 stocksMedical Laboratories Industry4th out of 19 stocks 4.4 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.85% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Guardant Health has recently increased by 25.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 2.4 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Guardant Health this week, compared to 4 articles on an average week.Search Interest21 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have bought 1,945.77% more of their company's stock than they have sold. Specifically, they have bought $38,972.00 in company stock and sold $1,905.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.49) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 13.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesApril 26, 2024 | bizjournals.comCompany developing early cancer-detection tests to cut 20% of workforceApril 26, 2024 | americanbankingnews.comGuardant Health (NASDAQ:GH) Coverage Initiated at Craig HallumApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 24, 2024 | stockhouse.comFDA Advisory Panel Review of Guardant Health's Shield(TM) Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 23, 2024 | americanbankingnews.comGuardant Health Sees Unusually High Options Volume (NASDAQ:GH)April 22, 2024 | finance.yahoo.comFDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 22, 2024 | businesswire.comFDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 18, 2024 | businesswire.comGuardant Health to Report First Quarter 2024 Financial Results on May 9, 2024April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 17, 2024 | msn.comMass. General Hospital granted unanimous approval to add dozens of inpatient bedsApril 17, 2024 | msn.comRomance Is In The Air On General HospitalApril 17, 2024 | msn.comGeneral Hospital Spoilers: Will Cyrus Decide Sonny's Prison Fate?April 17, 2024 | americanbankingnews.comGuardant Health (NASDAQ:GH) Reaches New 1-Year Low After Analyst DowngradeApril 16, 2024 | americanbankingnews.comGuardant Health (NASDAQ:GH) Price Target Cut to $28.00 by Analysts at The Goldman Sachs GroupApril 12, 2024 | yahoo.comGeneral Hospital Video Preview: Decisions, Disrespect, and DeceptionApril 12, 2024 | msn.comWhat The Heck Just Happened On General Hospital?April 4, 2024 | forbes.comGuardant HealthApril 1, 2024 | investorplace.comBetter Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.March 30, 2024 | yahoo.comGeneral Hospital Comings and Goings: Missing Doc Back, New CastingsMarch 17, 2024 | finance.yahoo.comGH Apr 2024 55.000 putMarch 16, 2024 | finance.yahoo.comGH Dec 2025 7.500 putMarch 16, 2024 | finance.yahoo.comGH Jul 2024 10.000 putMarch 15, 2024 | msn.comCell-Free DNA Test Has 83.1 Percent Sensitivity for Detection of CRCMarch 15, 2024 | msn.comCathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer UpdatesMarch 14, 2024 | ca.news.yahoo.comAlcohol recovery room at University of Guelph helps ease ER pressure, hospital saysMarch 13, 2024 | businesswire.comGuardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of MedicineMarch 6, 2024 | businesswire.comGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/26/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$39.27 High Stock Price Target$55.00 Low Stock Price Target$27.00 Potential Upside/Downside+125.4%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-85.02% Pretax Margin-84.89% Return on Equity-301.94% Return on Assets-27.65% Debt Debt-to-Equity Ratio7.18 Current Ratio6.54 Quick Ratio6.24 Sales & Book Value Annual Sales$563.95 million Price / Sales3.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book13.00Miscellaneous Outstanding Shares121,710,000Free Float114,167,000Market Cap$2.12 billion OptionableNot Optionable Beta0.87 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsVeracyteNASDAQ:VCYTRadNetNASDAQ:RDNTFortreaNASDAQ:FTREViridian TherapeuticsNASDAQ:VRDNFulgent GeneticsNASDAQ:FLGTView All CompetitorsInsiders & InstitutionsIMA Wealth Inc.Sold 1,235 shares on 4/25/2024Ownership: 0.013%Sumitomo Mitsui Trust Holdings Inc.Sold 26,051 shares on 4/19/2024Ownership: 0.261%Allspring Global Investments Holdings LLCBought 13,250 shares on 4/18/2024Ownership: 0.011%Nomura Holdings Inc.Bought 103,400 shares on 3/27/2024Ownership: 0.000%PNC Financial Services Group Inc.Sold 2,124 shares on 3/22/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price target for 2024? 13 Wall Street analysts have issued 1-year target prices for Guardant Health's shares. Their GH share price targets range from $27.00 to $55.00. On average, they anticipate the company's share price to reach $39.27 in the next twelve months. This suggests a possible upside of 125.2% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2024? Guardant Health's stock was trading at $27.05 at the beginning of the year. Since then, GH stock has decreased by 35.5% and is now trading at $17.44. View the best growth stocks for 2024 here. Are investors shorting Guardant Health? Guardant Health saw a increase in short interest in April. As of April 15th, there was short interest totaling 9,560,000 shares, an increase of 25.1% from the March 31st total of 7,640,000 shares. Based on an average trading volume of 1,990,000 shares, the days-to-cover ratio is presently 4.8 days. View Guardant Health's Short Interest. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GH earnings forecast. How can I listen to Guardant Health's earnings call? Guardant Health will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, February, 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.65. The company had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative trailing twelve-month return on equity of 301.94%. What ETFs hold Guardant Health's stock? ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Tema Oncology ETF (CANC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and ARK Genomic Revolution ETF (ARKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Guardant Health issued on next quarter's earnings? Guardant Health updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $655.0 million-$670.0 million, compared to the consensus revenue estimate of $669.4 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.26%), IMA Wealth Inc. (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Samir Kaul, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
